Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: CVS Health (CVS), Crispr Therapeutics AG (CRSP)

Tipranks - Tipranks - Wed Apr 8, 9:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS), Crispr Therapeutics AG (CRSP) and Quest Diagnostics (DGX) with bullish sentiments.

Easter Sale - 70% Off TipRanks

CVS Health (CVS)

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on CVS Health. The company’s shares closed last Tuesday at $76.34, close to its 52-week high of $80.75.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 11.8% and a 63.1% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Envista Holdings, and Cardinal Health. ;'>

CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $96.43, representing a 24.6% upside. In a report issued on March 30, Bernstein also maintained a Buy rating on the stock with a $94.00 price target.

See today’s best-performing stocks on TipRanks >>

Crispr Therapeutics AG (CRSP)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $80.00. The company’s shares closed last Tuesday at $48.37.

According to TipRanks.com, Kapoor is a 4-star analyst with an average return of 8.5% and a 38.7% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., Lexeo Therapeutics, Inc., and BioMarin Pharmaceutical. ;'>

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $71.29.

Quest Diagnostics (DGX)

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Quest Diagnostics. The company’s shares closed last Tuesday at $199.89.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.1% and a 47.3% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Quest Diagnostics is a Moderate Buy with an average price target of $221.11.

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).